reteplase (Retavase) Report issue

Biologics Recombinant protein Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Reteplase, trade names include Retavase, is a thrombolytic drug, used to treat heart attacks by breaking up the clots that cause them.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Alternative names

173-527-plasminogen activator (human tissue-type), 173-l-serine-174-l-tyrosine-175-l-glutamine- | bm 06022 | bm 06.022 | bm-06.022 | human t-pa (residues 1-3 and 176-527) | rapilysin | retavase | reteplase | reteplase,recombinant | reteplase, recombinant

Organizations (18)

Research & Development (17)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (9)

Approved Indications (1)


 

Myocardial Infarction (approved 1996)

Experimental Indications - Clinical Trial Phases 1-4 (9)


 

Catheterization, Central Venous (Phase 3)

Catheters (Phase 3)

Heart Diseases (Phase 4)

HIV (Phase 4)

Myocardial Infarction (Phase 4)

Pulmonary Embolism (Phase 2)

ST Elevation Myocardial Infarction (Phase 3)

Stroke (Phase 2)

Thrombosis (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 11
  • # of Trial Organizations: 17

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue